Lupin's share price saw significant selling, falling 1.84 percent to reach a low of ₹2,144.70 during the session. This decline followed a major global brokerage firm downgrading the pharmaceutical stock to a 'sell' rating. The firm also slashed its price target to ₹2,050, pointing to structural valuation challenges.
by shortkt.com✓